EUCTR2012-002542-20-ES进行中（未招募）不适用
Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma - ELDERLY
YSARC0 个研究点目标入组 633 人开始时间: 2015年1月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 633
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? signed informed consent form
- •? Biopsy-proven mantle cell lymphoma according to WHO classification, including evidence of cyclin D1 overexpression or the translocation t(11;14)(q13;q32).
- •? ? 60 years of age and ineligible for autologous transplant
- •? Ann Arbor stage II-IV
- •? previously untreated
- •? ECOG performance status ? 2
- •? Male subjects must:
- •- agree to use a condom during sexual contact with a woman of childbearing potential, even if they have had a vasectomy, throughout lenalidomide/placebo therapy
- •- agree to not donate semen during lenalidomide therapy.
- •? All subjects must:
- •- have an understanding that the lenalidomide could have a potential teratogenic risk.
- •- agree to abstain from donating blood while taking lenalidomide therapy
- •- agree not to share study medication with another person.
- •- be counseled about pregnancy precautions and risks of fetal exposure.
- •? Additional criteria for randomization in maintenance phase :
- •- CR, CRu or PR after induction treatment, determined as per Cheson 1999 criteria by investigator
- •- During the run-in period of 6 months starting from the date of the first patient randomized in the trial: in case of direct randomization into maintenance phase, patient must have been treated in first line by 6-8 cycles of R-CHOP.
- •To be randomized for maintenance, the patient must satisfy all inclusion criteria for randomization 1 and the following additional criteria:
- •- CR, CRu or PR after induction treatment, determined as per Cheson 1999 criteria (see Appendix G, {20} by investigator even for patients enrolled during the run-in phase.
- •- During the run-in period of 6 months starting from the date of the first randomization in the trial: in case of direct randomization into maintenance phase, patient must have been treated in first line by 6-8 cycles of R-CHOP
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •? Female of child-bearing potential (without natural menopause for at least 24 consecutive months, a hysterectomy or bilateral oophorectomy)
- •? Any of the following laboratory abnormalities, if not related to lymphoma:
- •- Absolute neutrophils count (ANC) <1,000 /mm3 (1.0 x 109/L) if not result of a BM infiltration.
- •- Platelet count < 75,000/mm3 (75 x 109/L) if not result of a BM infiltration.
- •- Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) >3.0 x upper limit of normal.
- •- Serum total bilirubin > 1.5 UNL (except if due to Gilbert?s syndrome)
- •? Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) < 30 mL /min.
- •? Central nervous system involvement by lymphoma
- •? Contraindication for medicamentous DVT prophylaxis
- •? Prior history of malignancies other than MCL unless the subject has been free of the disease for ? 5 years (Exceptions: Basal or squamous cell carcinoma of the skin, Carcinoma in situ of the cervix or of the breast, Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b).
- •? Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient to receive the study medication as planned.
- •? Poor cardiac fuction (LVEF < 50%) on echecardiography
- •? Seropositivity for human immunodeficiency virus (HIV, mandatory test)
- •Seropositivity for hepatitis C virus (HCV, mandatory test),
- •Active viral infection with hepatitis B virus (HBV, mandatory test):
- •- HBsAg positive
- •- HBsAg negative, anti-HBs positive and anti-HBc positive
- •? Uncontrolled illness including, but not limited to:
- •- Active infection requiring parenteral antibiotics
- •- Uncontrolled diabetes mellitus
- •- Chronic symptomatic congestive heart failure (Class NYHA III or IV).
- •- Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
- •- Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia.
- •? Prior ? Grade 3 allergic hypersensitivity to thalidomide.
- •? Prior ? Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
- •? Subjects with ? Grade 2 neuropathy.
- •? Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies
- •? Prior use of lenalidomide.
- •? Participation in another clinical trial within three weeks before randomization in this study
- •Additional exclusion criteria for randomization in maintenance phase:
- •- SD or PD after induction treatment determined as per Cheson 1999 criteria assessed by investigator.
- •- Patients who had not received at least 6 cycles of R-CHOP21 or 2 cycles of R-CHOP21 / 2 cycles of R-HAD28 (alternating)
- •- Patients with serious underlying medical conditions, which could impair the ability to receive maintenance treatment
- •- Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of < 30 mL /min at screening for maintenance.
- •- ANC < 1,000 cells/mm³ (1.0 X 109/L) at screening for maintenance;
- •- Platelet count < 50,000 cells/mm³ (50 X 109/L) at screening for maintenance.
- •The presence of any exclusion criteria of randomization 1 or of the following criteria will exclude a subject from enrollment in the maintenance phase:
- •- SD or PD after induction treatment determined as per Cheson 1999 criteria (see Appendix G, {25} by investigator.
- •- Patient treated by induction immuno-chemotherapy other than 6-8 cycle of R-CHOP21 or 2-3 cycles of R-CHOP21 / 2-3 cycles of R-HAD28 (alternating)
- •- Patients with seri
研究者
相似试验
进行中（未招募）
1 期
Efficacy of therapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of lenalidomide + rituximab versus rituximab alone for older patients with mantle cell lymphomaMantle Cell LymphomaEUCTR2012-002542-20-NLYSARC633
招募中
3 期
Efficacy of alternating immunochemotherapy consisting of RCHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma10025322Mantle Cell LymphomaNL-OMON54774YSARC (The Lymphoma Academic Research Organisation)75
进行中（未招募）
1 期
Study to evaluate the efficacy of therapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of lenalidomide + rituximab versus rituximab alone for older patients with mantle cell lymphomaMantle Cell LymphomaEUCTR2012-002542-20-PTYSARC633
进行中（未招募）
1 期
Efficacy of therapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of lenalidomide + rituximab versus rituximab alone for older patients with mantle cell lymphomaMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Mantle Cell LymphomaEUCTR2012-002542-20-DEYSARC633
进行中（未招募）
1 期
Efficacy of therapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of lenalidomide + rituximab versus rituximab alone for older patients with mantle cell lymphomaMantle Cell LymphomaMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002542-20-BEYSARC633